Susquehanna International Group
MDGL icon

Susquehanna International Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Susquehanna International Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.5M Buy
163,300
+41,500
+34% +$19.8M 0.01% 926
2025
Q4 		$70.9M Sell
121,800
-20,200
-14% -$10.3M 0.01% 1103
2025
Q3 		$65.1M Buy
142,000
+68,600
+93% +$25.6M 0.01% 1163
2025
Q2 		$22.2M Sell
73,400
-109,600
-60% -$32.7M ﹤0.01% 1900
2025
Q1 		$60.6M Sell
183,000
-89,900
-33% -$29.5M 0.01% 920
2024
Q4 		$84.2M Buy
272,900
+40,900
+18% +$11.5M 0.01% 818
2024
Q3 		$49.2M Sell
232,000
-105,800
-31% -$27.1M 0.01% 1095
2024
Q2 		$94.6M Sell
337,800
-92,700
-22% -$22.1M 0.02% 630
2024
Q1 		$115M Buy
430,500
+195,400
+83% +$46M 0.02% 601
2023
Q4 		$54.4M Sell
235,100
-135,900
-37% -$23.8M 0.01% 986
2023
Q3 		$54.2M Sell
371,000
-4,700
-1% -$885K 0.01% 960
2023
Q2 		$86.8M Buy
375,700
+124,400
+50% +$33.7M 0.02% 681
2023
Q1 		$60.9M Buy
251,300
+29,300
+13% +$7.98M 0.01% 834
2022
Q4 		$64.4M Buy
222,000
+186,000
+517% +$18.2M 0.02% 753
2022
Q3 		$2.34M Sell
36,000
-18,700
-34% -$1.3M ﹤0.01% 4611
2022
Q2 		$3.92M Buy
54,700
+37,400
+216% +$2.75M ﹤0.01% 3609
2022
Q1 		$1.7M Sell
17,300
-15,000
-46% -$1.26M ﹤0.01% 5844
2021
Q4 		$2.74M Buy
32,300
+6,700
+26% +$550K ﹤0.01% 4815
2021
Q3 		$2.04M Buy
25,600
+16,700
+188% +$1.44M ﹤0.01% 5789
2021
Q2 		$867K Buy
8,900
+900
+11% +$107K ﹤0.01% 8165
2021
Q1 		$936K Buy
8,000
+600
+8% +$70K ﹤0.01% 7916
2020
Q4 		$823K Sell
7,400
-16,400
-69% -$2M ﹤0.01% 7167
2020
Q3 		$2.83M Sell
23,800
-18,100
-43% -$1.97M ﹤0.01% 3975
2020
Q2 		$4.75M Buy
41,900
+36,000
+610% +$3.54M ﹤0.01% 3083
2020
Q1 		$394K Buy
+5,900
New +$492K ﹤0.01% 7439
2019
Q4 		– Sell
-15,600
Closed -$1.34M – 10262
2019
Q3 		$1.34M Sell
15,600
-33,600
-68% -$3.15M ﹤0.01% 5060
2019
Q2 		$5.16M Sell
49,200
-84,400
-63% -$9.04M ﹤0.01% 2669
2019
Q1 		$16.7M Sell
133,600
-46,900
-26% -$5.83M 0.01% 1311
2018
Q4 		$20.3M Buy
180,500
+12,200
+7% +$1.89M 0.01% 1057
2018
Q3 		$36M Buy
168,300
+41,500
+33% +$10.4M 0.01% 881
2018
Q2 		$35.5M Buy
+126,800
New +$22.3M 0.01% 886
2016
Q1 		– Sell
-811
Closed -$10K – 9408
2015
Q4 		$10K Sell
811
-940
-54% -$25.8K ﹤0.01% 9292
2015
Q3 		$107K Sell
1,751
-1,626
-48% -$117K ﹤0.01% 9103
2015
Q2 		$264K Buy
3,377
+791
+31% +$66.4K ﹤0.01% 8773
2015
Q1 		$176K Sell
2,586
-1,614
-38% -$138K ﹤0.01% 8708
2014
Q4 		$390K Sell
4,200
-1,431
-25% -$148K ﹤0.01% 7698
2014
Q3 		$593K Sell
5,631
-63
-1% -$8.76K ﹤0.01% 6901
2014
Q2 		$815K Buy
5,694
+1,103
+24% +$161K ﹤0.01% 6475
2014
Q1 		$693K Sell
4,591
-5,403
-54% -$1.06M ﹤0.01% 6174
2013
Q4 		$1.83M Sell
9,994
-5,463
-35% -$1M ﹤0.01% 4432
2013
Q3 		$3.41M Sell
15,457
-6,514
-30% -$1.39M ﹤0.01% 3282
2013
Q2 		$3.84M Buy
+21,971
New +$5.73M ﹤0.01% 2973

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's MDGL Position: Q1 2026 in Review

Susquehanna International Group reduced its Madrigal Pharmaceuticals (MDGL) stake by 66% in Q1 2026, selling an estimated $20.2M and leaving 22,216 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2887.

Susquehanna International Group first reported a position in MDGL in Q2 2013 and has held it in 42 quarters since. The position peaked at $48.1M in Q3 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Susquehanna International Group held 22,216 shares of Madrigal Pharmaceuticals worth $11.6M as of Q1 2026.
  • Susquehanna International Group sold 42,250 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $20.2M.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2887 holding.
  • Susquehanna International Group first reported a position in Madrigal Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Susquehanna International Group's Madrigal Pharmaceuticals position peaked at $48.1M in Q3 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.